

Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024*

POTENTIAL APPROVALS US/EU

	US	OPSUMIT (macitentan)
	EU	Pediatric Pulmonary Arterial Hypertension (TOMORROW)
✓	US	OPSYNVI (macitentan/tadalafil STCT)
	EU	Pulmonary Arterial Hypertension
✓	US	EDURANT (rilpivirine)
	EU	HIV pediatric 2-12 year old
✓	US [^]	BALVERSA (erdafitinib)
	EU	Urothelial Cancer (THOR)
	US	DARZALEX (daratumumab)
	EU	Frontline multiple myeloma transplant eligible (PERSEUS)
✓	US	CARVYKTI (ciltacabtagene autoleucel)
	EU	Relapsed Refractory multiple myeloma w/1-3 PL (CARITUDE-4)
✓	US	RYBREVANT (amivantamab)
	EU	Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)
	US	RYBREVANT / lazertinib
	EU	Non Small Cell Lung Cancer 2L (MARIPOSA-2)
	US	RYBREVANT / lazertinib
	EU	Non Small Cell Lung Cancer (MARIPOSA)

PLANNED SUBMISSIONS US/EU

US	OPSUMIT (macitentan)	
EU	Pediatric Pulmonary Arterial Hypertension (TOMORROW)	
	UPTRAVI (selexipag)	
EU	Pediatric Pulmonary Arterial Hypertension (SALTO)	
US	nipocalimab	
EU	Generalized Myasthenia Gravis	
US	RYBREVANT (amivantamab)	
EU	Subcutaneous (PALOMA-3)	
✓	US	DARZALEX (daratumumab)
✓	EU	Frontline multiple myeloma transplant eligible (PERSEUS)
	REKAMBYS	
EU	HIV Adolescents	

US	SIMPONI (golimumab)	
EU	Pediatric Ulcerative Colitis	
	STELARA (ustekinumab)	
EU	Pediatric Crohn's Disease	
US	TREMFYA (guselkumab)	
EU	Pediatric Psoriasis	
US	TREMFYA (guselkumab)	
EU	Crohn's Disease (GALAXI)	
US	TREMFYA (guselkumab)	
EU	Pediatric Juvenile Psoriatic Arthritis	
✓	US	TREMFYA (guselkumab)
EU	Ulcerative Colitis Monotherapy (QUASAR)	
US	TREMFYA (guselkumab)	
EU	Ulcerative Colitis Subcutaneous Induction (ASTRO)	
US	TREMFYA (guselkumab)	
EU	Crohn's Disease Subcutaneous Induction (GRAVITI)	

POTENTIAL CLINICAL DATA

Phase III

TREMFYA (guselkumab)
Crohn's Disease (GALAXI)
TREMFYA (guselkumab)
Ulcerative Colitis Monotherapy (QUASAR)
RYBREVANT (amivantamab)
Subcutaneous (PALOMA-3)
ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)
seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms
nipocalimab
Generalized Myasthenia Gravis
TREMFYA (guselkumab)
Crohn's Disease Subcutaneous Induction (GRAVITI)
aticaprant
Adjunctive Major Depressive Disorder
SPRAVATO (esketamine) monotherapy
Treatment Resistant Depression (TRD4005)

Phase II

Combination Therapy
Psoriatic Arthritis
nipocalimab
Sjogren's Disease
TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer (SunRISe-1)



*This information is as of April 16, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval

✓ = Achieved